News Column

Researchers at Ohio State University Report New Data on Cancer Gene Therapy

February 10, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting originating from Columbus, Ohio, by NewsRx correspondents, research stated, "Despite substantial progress in understanding the cancer signaling network, effective therapies remain scarce due to insufficient disruption of oncogenic pathways, drug resistance and drug-induced toxicity. New and more creative approaches are therefore required for the treatment of cancer."

Our news editors obtained a quote from the research from Ohio State University, "MicroRNAs (miRNAs) are a family of small noncoding RNAs that regulate gene expression by sequence-selective targeting of mRNAs, leading to a translational repression or mRNA degradation. Experimental evidence demonstrates that dysregulation of specific miRNAs leads to drug resistance in different cancers and correction of these miRNAs using miRNA mimics or antagomiRs can normalize the gene regulatory network and signaling pathways and sensitize cancerous cells to chemotherapy. Therefore, miRNA-based gene therapy provides an attractive anti-tumor approach for integrated cancer therapy."

According to the news editors, the research concluded: "Here, we will discuss the involvement of microRNAs in chemotherapy resistance and focus on recent advancements in the development and delivery of miRNA-based cancer therapeutics."

For more information on this research see: MicroRNAs as therapeutic targets in chemoresistance. Drug Resistance Updates, 2013;16(3-5):47-59. Drug Resistance Updates can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Drug Resistance Updates - www.elsevier.com/wps/product/cws_home/623026)

The news editors report that additional information may be obtained by contacting M. Garofalo, Ohio State University, Center Comprehens Canc, Dept. of Mol Virol Immunol & Med Genet, Columbus, OH 43210, United States (see also Biotechnology).

Keywords for this news article include: Ohio, Biotechnology, Drugs, Columbus, Oncology, Chemotherapy, United States, Bioengineering, Cancer Gene Therapy, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools